Rapt Therapeutics, Inc. Stock Price, News & Analysis

RAPT Therapeutics (NASDAQ: RAPT) reported its Q1 2025 financial results, showing a significant improvement in net loss to $17.2 million compared to $30.5 million in Q1 2024. Research and development expenses decreased to $12.0 million from $24.8 million year-over-year, while G&A expenses slightly decreased to $7.2 million from $7.7 million. The company maintained a strong cash position of $179.3 million as of March 31, 2025.

CEO Brian Wong highlighted progress with RPT904, their food allergy treatment candidate, with plans to initiate a Phase 2b trial in H2 2025. The company is also anticipating clinical data for RPT904 in chronic spontaneous urticaria (CSU) from their partner Jemincare later this year.

RAPT Therapeutics (RAPT) has appointed Dr. Jessica Savage as Vice President of Clinical Development to lead the development of RPT904, a novel monoclonal antibody targeting immunoglobin E (IgE) for allergic diseases. The company plans to initiate a Phase 2b clinical trial for food allergy in the second half of 2025, with additional focus on chronic spontaneous urticaria (CSU).

Dr. Savage, a board-certified allergist and immunologist, brings significant expertise in food allergy research and clinical development. Her previous experience includes roles at Harvard Medical School, Johns Hopkins University, and leadership positions at Alexion, where she led clinical development strategies for various treatments. She was also involved in development programs for medications like Empaveli®, Trikafta®, and Bylvay®.

RAPT Therapeutics (Nasdaq: RAPT), a clinical-stage biopharmaceutical company specializing in immunology-based therapies, has announced its participation in two major investor conferences in March 2025. The company, which focuses on developing treatments for inflammatory and immunological diseases, will be featured in:

• The Leerink Global Healthcare Conference with a fireside chat scheduled for March 11, 2025 at 3:40 p.m. ET
• The Barclays 27th Annual Global Healthcare Conference with a fireside chat planned for March 12, 2025 at 10:30 a.m. ET

Interested parties can access live webcasts and archived recordings of these discussions through the company's investor relations website at investors.rapt.com/events-and-presentations.

RAPT Therapeutics reported its Q4 and full-year 2024 financial results, highlighting its focus on advancing RPT904, a novel therapy for food allergy and chronic spontaneous urticaria. The company's Q4 2024 net loss widened to $53.2 million from $30.9 million in Q4 2023.

Key financial highlights include:

• R&D expenses increased to $46.5M in Q4 2024, primarily due to a $35M upfront license fee for RPT904
• Full-year 2024 net loss reached $129.9M compared to $116.8M in 2023
• Secured $143M through private placement of shares and warrants in December 2024
• Cash position of $231.1M as of December 31, 2024

The company entered a license agreement with Jemincare for RPT904, potentially worth up to $672.5M in milestone payments plus royalties. RAPT plans to initiate a Phase 2b trial for RPT904 in food allergy in H2 2025.

RAPT Therapeutics (Nasdaq: RAPT), a clinical-stage biopharmaceutical company specializing in immunology-based therapies, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Brian Wong, M.D., Ph.D., will deliver a company overview presentation on Thursday, January 16, 2025, at 9:00 a.m. Pacific Time.

The presentation will be accessible via live webcast, and an archived recording will be available on the company's investor relations website. RAPT Therapeutics focuses on developing novel treatments for patients with inflammatory and immunological diseases.

RAPT Therapeutics has appointed Lori Lyons-Williams as the new chair of its board of directors, effective January 3, 2025. She succeeds William Rieflin, who will remain as a consultant. Lori has been a board member for four years and brings over 20 years of experience in the biotech and pharmaceutical industries. She is currently the President and CEO of Abdera Therapeutics and has held significant roles at Neumora Therapeutics, Dermira, and Allergan. Her expertise includes the successful launch of multiple commercial products, including BOTOX®. Brian Wong, President and CEO of RAPT, expressed confidence in Lori's ability to guide the company through late-stage development and commercialization efforts, particularly in the field of inflammatory diseases. William Rieflin, who led the board for nine years, expressed his confidence in the board and management team under Lori's leadership.

RAPT Therapeutics has announced a $150 million private placement through the sale of 100,000,000 shares of common stock at $0.85 per share and pre-funded warrants for up to 76,452,000 shares at $0.8499 per warrant. The placement, expected to close around December 27, 2024, was led by The Column Group and TCGX, with participation from several prominent investors including BVF Partners LP, Deep Track Capital, and others.

The pre-funded warrants will have an exercise price of $0.0001 per share and will be immediately exercisable. The proceeds will fund research and development of the company's pipeline and general corporate purposes. The company has agreed to file a registration statement for the resale of the shares and warrant-underlying shares.

RAPT Therapeutics and Shanghai Jemincare Pharmaceutical have entered into an exclusive license agreement for JYB1904 (RPT904), a clinical-stage anti-IgE antibody. RAPT obtains worldwide rights excluding China, Hong Kong, Macau, and Taiwan for a $35 million upfront payment, up to $672.5 million in milestone payments, and high single-digit to low-double digit royalties.

RPT904 is being developed as a potential improvement over omalizumab (Xolair®), targeting the same epitope but with an extended half-life. Jemincare's Phase 1 study showed good safety profile and a half-life more than twice that of omalizumab. RAPT plans to initiate a Phase 2b trial in food allergy in the second half of 2025, while Jemincare is conducting Phase 2 trials in asthma and chronic spontaneous urticaria in China.